<SEC-DOCUMENT>0001520138-22-000306.txt : 20220715
<SEC-HEADER>0001520138-22-000306.hdr.sgml : 20220715
<ACCEPTANCE-DATETIME>20220715171206
ACCESSION NUMBER:		0001520138-22-000306
CONFORMED SUBMISSION TYPE:	PRE 14C
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20220715
FILED AS OF DATE:		20220715
DATE AS OF CHANGE:		20220715

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOVIE INC.
		CENTRAL INDEX KEY:			0001580149
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				462510769
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		PRE 14C
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39015
		FILM NUMBER:		221087561

	BUSINESS ADDRESS:	
		STREET 1:		680 W NYE LANE
		STREET 2:		SUITE 201
		CITY:			CARSON CITY
		STATE:			NV
		ZIP:			89703
		BUSINESS PHONE:		775-888-3162

	MAIL ADDRESS:	
		STREET 1:		680 W NYE LANE
		STREET 2:		SUITE 201
		CITY:			CARSON CITY
		STATE:			NV
		ZIP:			89703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NANOANTIBIOTICS, INC.
		DATE OF NAME CHANGE:	20130625
</SEC-HEADER>
<DOCUMENT>
<TYPE>PRE 14C
<SEQUENCE>1
<FILENAME>bivi-20220715_14cpre.htm
<DESCRIPTION>PRE 14C
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 3pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0; text-align: center"><B>SCHEDULE 14C</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0; text-align: center">Information Statement Pursuant to Section 14(c)<BR>
of the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0; text-align: center">(Amendment No. )<BR>
<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0; text-align: justify">Check the appropriate box:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Preliminary Information Statement</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Confidential, for Use of Commission Only (as permitted by Rule 14c-5(d)(2))</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Definitive Information Statement</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-size: 14pt"><B>BIOVIE INC.<BR>
</B></FONT><FONT STYLE="font-size: 10pt">(Name of Registrant as Specified in its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">Payment of Filing Fee (Check all boxes that
apply):</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">No fee required.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Fee paid previously with preliminary materials</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Fee computed on table in exhibit required by Item 25(b) of Schedule 14A (17 CFR 240.14a-101) per Item 1 of this Schedule and Exchange Act Rules 14c-5(g) and 0-11</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 3pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->
<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>BIOVIE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">680 W Nye Lane Suite 201</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Carson City, NV 89703</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>NOTICE
OF STOCKHOLDER ACTION BY WRITTEN CONSENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0">To the Stockholders of BioVie Inc.:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">This Notice and the accompanying Information
Statement are being furnished to the stockholders of record of the Class A common stock, par value $0.0001 per share (the &#8220;Common
Stock&#8221;), of BioVie Inc., a Nevada corporation (the &#8220;Company&#8221;), in connection with action taken by Acuitas Group Holdings,
LLC (the &#8220;Majority Stockholder&#8221;), the holder of a majority of the issued and outstanding voting securities of the Company,
approving in accordance with Nasdaq Listing Rule 5635(c) and 5635(d) (collectively, &#8220;Nasdaq Rule 5635&#8221;), by written consent
in lieu of a special meeting dated July 15, 2022, the issuance to the Majority Stockholder in a private placement by the Company of (i)
shares of Common Stock and (ii) a warrant to purchase shares of Common Stock (the &#8220;Warrant Shares&#8221;), (the &#8220;PIPE Financing&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0; text-align: justify">The approval of the PIPE Financing for purposes
of Nasdaq Rule 5635 was taken by written consent pursuant to Section 78.320(2) of the Nevada Revised Statutes and Article II, Section
7 of the Company&#8217;s Amended and Restated Bylaws (the &#8220;Bylaws&#8221;), which provides that any action that may be taken at any
annual or special meeting of stockholders may be taken without a meeting, without prior notice and without a vote, if a consent or consents
in writing, setting forth the action so taken, shall be signed by the holders of outstanding Common Stock having not less than the minimum
number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were
present and voted. The Company has obtained the approval of stockholders holding a majority of the Company&#8217;s issued and outstanding
shares of Common Stock for such stock issuance as required by the Nasdaq Listing Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">This Information Statement is being mailed on or about ________ __, 2022, to stockholders
of record as of July 15, 2022, referred to as the record date. The information statement is being delivered only to inform you of the
corporate action described herein before it takes effect in accordance with Rule 14c-2 promulgated under the Exchange Act. The action
shall be effective on or about ________ __, 2022, or approximately 20 days after we mail this Information Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0; text-align: justify"><B>WE ARE NOT ASKING YOU FOR A PROXY AND YOU
ARE REQUESTED NOT TO SEND US A PROXY.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0; text-align: justify">Your vote or consent is not requested or required
to approve the PIPE Financing. The accompanying Information Statement is provided solely for your information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0; text-align: justify">The Company is mailing this Notice and the accompanying Information Statement to stockholders on or
about ________ __, 2022. This Information Statement will serve as written notice to the stockholders of the Company pursuant to the Company&rsquo;s
Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>THIS IS NOT A NOTICE OF A MEETING OF STOCKHOLDERS
AND NO STOCKHOLDERS&#8217; MEETING WILL BE HELD TO CONSIDER ANY MATTER DESCRIBED HEREIN.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0.25pt; font: 12pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 50%; padding: 0.25pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">By Order of the Board of Directors,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Cuong V. Do</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Chief Executive Officer</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Dated: July __, 2022</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0">&nbsp;</P>



<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1.5pt solid; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>INFORMATION STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BIOVIE INC.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="toc"></A>TABLE OF CONTENTS<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP></SUP></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0">&nbsp;</P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; width: 80%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="text-align: right; font-weight: bold; border-bottom: Black 1.5pt solid; width: 10%; vertical-align: bottom">PAGE</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_001">GENERAL INFORMATION</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#a_001">1</A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2"><A HREF="#a_002">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS&nbsp;</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_002">3</A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><A HREF="#a_003">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT&nbsp;</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_003">4</A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2"><A HREF="#a_004">APPROVAL OF THE PIPE FINANCING FOR PURPOSES OF NASDAQ RULE 5635&nbsp;</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_004">6</A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_005">DISSENTERS&rsquo; RIGHTS OF APPRAISAL&nbsp;</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#a_005">8</A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2"><A HREF="#a_006">DELIVERY OF DOCUMENTS TO SECURITY HOLDERS SHARING AN ADDRESS&nbsp;</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_006">8</A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_007">WHERE YOU CAN FIND MORE INFORMATION</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#a_007">9</A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#a_008">OTHER MATTERS&nbsp;</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#a_008">10</A></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Exhibit A: Written Consent of The Majority Stockholder To Action Taken
Without A Meeting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 5pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 5pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0; text-align: center; color: red"><FONT STYLE="text-transform: uppercase"><B>PRELIMINARY
INFORMATION STATEMENT &#8212; SUBJECT TO COMPLETION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>INFORMATION STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BIOVIE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>680 W Nye Lane Suite 201</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Carson City,&nbsp;NV 89703</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(775) 888-3162</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>INFORMATION STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 14(C)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AND RULE 14C-2 THEREUNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>July 15, 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">NO VOTE OR OTHER ACTION OF THE COMPANY&#8217;S STOCKHOLDERS
IS REQUIRED IN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONNECTION WITH THIS INFORMATION STATEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0; text-align: center"><B>WE ARE NOT ASKING YOU FOR A PROXY AND YOU
ARE REQUESTED NOT TO SEND US A PROXY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_001"></A>General
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">BioVie Inc., a Nevada corporation (&ldquo;BioVie,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo;
or &ldquo;us&rdquo;), is sending you this Information Statement solely for purposes of informing its stockholders of record as of July
15, 2022 (the &ldquo;Record Date&rdquo;), in the manner required by Regulation 14C of the Securities Exchange Act of 1934, as amended
(the &ldquo;Exchange Act&rdquo;), and the Company&rsquo;s amended and restated bylaws (the &ldquo;Bylaws&rdquo;), of the action taken
by written consent by Acuitas Group Holdings, LLC, an entity controlled by Terren Peizer, Company&rsquo;s Chairman (the &ldquo;Majority
Stockholder&rdquo; or &ldquo;Purchaser&rdquo;), the holder of a majority of the issued and outstanding voting securities of the Company,
to approve, for purposes of Nasdaq Listing Rule 5635(c) and 5635(d) (collectively, &ldquo;Nasdaq Rule 5635&rdquo;), the issuance to the
Majority Stockholder in a private placement by the Company of (i) shares of the Company&rsquo;s Class A common stock, par value $0.0001
per share (the &ldquo;Common Stock&rdquo;) and (ii) a warrant (the &ldquo;Warrant&rdquo;) to purchase shares of Common Stock (the &ldquo;Warrant
Shares&rdquo;), on the terms and subject to the conditions set forth in the Securities Purchase Agreement, dated July 15, 2022 (the &ldquo;Purchase
Agreement&rdquo;), between the Company and the Purchaser (the &ldquo;PIPE Financing&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s Common Stock is listed on the
Nasdaq Capital Market, and the Company is subject to Nasdaq&#8217;s rules and regulations, including Nasdaq Rule 5635. Nasdaq Rule 5635,
subsections (c) and (d), requires stockholder approval prior to certain issuances of securities, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
issuance of securities in a transaction (other than a public offering) to officers, directors, employees or consultants at a discount
to the market value (the consolidated closing bid price immediately preceding the time the company enters into a binding agreement to
issue the securities) (the &#8220;Current Market Price&#8221;); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
issuance in a transaction (other than a public offering) of common stock (or securities convertible into or exercisable for common stock)
equal to 20% or more of the outstanding common stock or 20% or more of the voting power of a company for a purchase price that is lower
than (i) the Nasdaq Official Closing Price (as reflected on Nasdaq.com) immediately preceding the signing of a binding agreement; or (ii)
the average Nasdaq Official Closing Price of the common stock (as reflected on Nasdaq.com) for the five trading days immediately preceding
the signing of the binding agreement (such lower amount, the &#8220;Minimum Price&#8221;).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 10pt 0; text-align: justify">Under Nevada law and our Bylaws, any action
that can be taken at an annual or special meeting of stockholders may be taken without a meeting, without prior notice and without a
vote, if a consent in writing, setting forth the action so taken, shall be signed by the holders of a majority of the outstanding
shares entitled to vote. On the Record Date, the Company was authorized to issue 800,000,000 shares of Common Stock and there were
24,893,083 shares of Common Stock issued and outstanding with the holders thereof being entitled to cast one vote per share.</P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">On July 15, 2022, the board of directors of the Company (with the Majority
Stockholder abstaining) adopted resolutions approving the transactions in connection with the PIPE Financing. In connection with the adoption
of these resolutions, the board of directors had been informed that holders of a majority of our outstanding shares of Common Stock were
in favor of this proposal and would enter into a written consent approving the PIPE Financing. On July 15, 2022, the Majority Stockholder,
who holds a total of 19,529,846 shares of our Common Stock, representing 78.2% of our outstanding shares of Common Stock as of the Record
Date, consented in writing to the PIPE Financing (the &ldquo;Stockholder Consent&rdquo;). The full text of the Stockholder Consent is
attached hereto as <U>Exhibit A</U>. As described below, the Majority Stockholder is also the sole purchaser in the PIPE Financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0; text-align: justify">Accordingly, all necessary corporate approvals
in connection with the PIPE Financing have been obtained and this Information Statement is furnished solely for the purpose of informing
the stockholders of the Company in the manner required under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).
The general effect of the PIPE Financing is described in &#8220;APPROVAL OF THE PIPE FINANCING FOR PURPOSES OF NASDAQ RULE 5635&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The Company knows of no other matters other than
that described in this Information Statement which have been recently approved or considered by the holders of the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_002"></A>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Information Statement contains
forward-looking statements within the meaning of Section 21E of the Exchange Act and Section 27A of the Securities Act of 1933, as amended
(the &#8220;Securities Act&#8221;). Any statements contained in this Information Statement that are not statements of historical fact
may be forward-looking statements, including, without limitation, the timing of and the anticipated benefits of the PIPE Financing. When
we use the words &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continues,&#8221;
&#8220;anticipates,&#8221; &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;believes,&#8221; &#8220;should,&#8221; &#8220;could,&#8221;
&#8220;may,&#8221; &#8220;will&#8221; or the negative of these terms or other comparable terminology, we are identifying forward-looking
statements. Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors which could
cause actual events or results to differ from those expressed or implied by the forward-looking statements. Factors that might cause such
a difference include, but are not limited to, those discussed in our periodic reports filed with the SEC, including those discussed in
the &#8220;Risk Factors&#8221; section in Part I, Item 1A of our Annual Report on Form 10-K filed with the SEC on August 30, 2021 and
the following factors::</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 40.5pt; text-align: justify; text-indent: -4.5pt">- the risk of substantial dilution
from future issuances of our equity securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 40.5pt; text-align: justify; text-indent: -4.5pt">- our limited operating
history and experience in developing and manufacturing drugs;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 40.5pt; text-align: justify; text-indent: -4.5pt">- that none of our products
are approved for commercial sale;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 40.5pt; text-align: justify; text-indent: -4.5pt">- our substantial capital
needs;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">- product development risks;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 40.5pt; text-align: justify; text-indent: -4.5pt">- our lack of sales and
marketing personnel;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 40.5pt; text-align: justify; text-indent: -4.5pt">- regulatory, competitive
and contractual risks;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 40.5pt; text-align: justify; text-indent: -4.5pt">- no assurance that
our product candidates will obtain regulatory approval or that the results of clinical studies will be favorable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 40.5pt; text-align: justify; text-indent: -4.5pt">- risks related to our intellectual
property rights;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 40.5pt; text-align: justify; text-indent: -4.5pt">- uncertainty of
successful development of biopharmaceuticals;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 40.5pt; text-align: justify; text-indent: -4.5pt">- the volatility of the
market price and trading volume of our common stock;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -4.5pt">- the other risks set forth in the documents
incorporated by reference herein under the caption &#8220;Risk Factors.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; text-indent: 0.5in">Except as may be required by applicable
law, the Company does not undertake or intend to update or revise any forward-looking statements, and the Company assumes no obligation
to update any forward-looking statements contained in this Information Statement as a result of new information or future events or developments.
Thus, you should not assume that the Company&#8217;s silence over time means that actual events are bearing out as expressed or implied
in such forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0; text-align: center"><A NAME="a_003"></A><B>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
OWNERS AND MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Based solely upon information made available
to the Company, the following table sets forth information as of the Record Date regarding the beneficial ownership of the Company&#8217;s
Common Stock by:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 36px">&nbsp;</TD>
    <TD STYLE="width: 36px; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">each person known by the Company to be the beneficial owner of more than 5% of the Company&#8217;s outstanding shares of Common Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 36px">&nbsp;</TD>
    <TD STYLE="width: 36px; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">each of the Company&#8217;s named executive officers and directors; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 36px">&nbsp;</TD>
    <TD STYLE="width: 36px; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">all of the Company&#8217;s officers and directors as a group.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The percentage ownership information shown
in the table is based upon 24,893,083 shares of Common Stock outstanding as of the Record Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Beneficial ownership is determined in accordance
with the rules of the SEC and includes voting or investment power with respect to the securities. Except as otherwise indicated, each
person or entity named in the table has sole voting and investment power with respect to all shares of the Company&#8217;s capital shown
as beneficially owned, subject to applicable community property laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In computing the number and percentage of shares
beneficially owned by a person as of a particular date, shares that may be acquired by such person (for example, upon the exercise of
options or warrants) within 60 days of such date are counted as outstanding, while these shares are not counted as outstanding for computing
the percentage ownership of any other person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The address of each holder listed below, except
as otherwise indicated, is c/o BioVie Inc., 680 W Nye Lane Suite 201, Carson City, NV 89703.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Name and Address of Beneficial Owner</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Common Shares Before PIPE Financing</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Percentage Before PIPE Financing</B></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Common Shares After PIPE Financing</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Percentage After PIPE Financing</B></P></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 12pt">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 12pt">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 12pt">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 12pt">&nbsp;</TD><TD STYLE="font-size: 12pt">&nbsp;</TD>
    <TD STYLE="font-size: 12pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left; padding-left: 5.65pt"><FONT STYLE="font-size: 10pt">Terren Peizer <SUP>(1)</SUP></FONT></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right">19,529,846</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right">78.2</TD>
    <TD STYLE="width: 1%; text-align: left">%</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right">30,438,938</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 3%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 12%; font-weight: bold; text-align: right">84.8%</TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.65pt"><FONT STYLE="font-size: 10pt">Cuong Do <SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">521,241</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.1</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">521,241</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: right">1.8%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.65pt"><FONT STYLE="font-size: 10pt">Joanne Wendy Kim <SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,100</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,100</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.65pt"><FONT STYLE="font-size: 10pt">Joe Palumbo <SUP>(4)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,883</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,883</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.65pt"><FONT STYLE="font-size: 10pt">Penny Markham <SUP>(5)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,593</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,593</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.65pt"><FONT STYLE="font-size: 10pt">Chris Reading <SUP>(6)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,700</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44700</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.65pt"><FONT STYLE="font-size: 10pt">Clarence Ahlem <SUP>(6)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44.700</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,700</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.65pt"><FONT STYLE="font-size: 10pt">Richard Berman <SUP>(7)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">85,913</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">85,913</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.65pt"><FONT STYLE="font-size: 10pt">Steve Gorlin <SUP>(8)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">128,713</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">128,713</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.65pt"><FONT STYLE="font-size: 10pt">Robert Hariri <SUP>(9)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78,513</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78,513</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.65pt"><FONT STYLE="font-size: 10pt">James Lang <SUP>(10)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">126,707</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">126,707</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.65pt"><FONT STYLE="font-size: 10pt">Sigmund Rogich <SUP>(11)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">79,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">79,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.65pt"><FONT STYLE="font-size: 10pt">Michael Sherman <SUP>(12)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">121,572</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">121,572</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center; padding-left: 5.65pt">All directors and executive officers as a group</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">20,893,980</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">83.6</TD><TD STYLE="font-weight: bold; text-align: left">%</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt"><B>31,803,072</B></FONT></TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: right">89.5%</TD></TR>
  </TABLE>
<P STYLE="font: 3pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
<P STYLE="text-indent: 20pt; font: 7pt Times New Roman, Times, Serif; margin: 0; text-align: justify">_________________________________</P>

<P STYLE="text-indent: 20pt; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">*Less than 1%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20px; text-align: right"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 7px">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes warrants to purchase 7,272,724 shares of Common Stock. All shares held of record by Acuitas Group Holdings, LLC, a limited liability company 100% owned by Terren Peizer, and as to which, Mr. Peizer may be deemed to beneficially own or control. Mr. Peizer disclaims beneficial ownership of any such securities.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20px; text-align: right"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="width: 7px">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes warrants to purchase 70,667 shares of Common Stock and options to purchase 294,975 shares of Common Stock, which are exercisable within 60 days of July 15, 2022. All shares of Common Stock, warrants and options are held of record by Mr. Do or Do &amp; Rickles Investments, LLC, a limited liability company 100% owned by Cuong Do and his wife, and as such, Mr. Do may be deemed to beneficially own or control.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20px; text-align: right"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="width: 7px">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes options to purchase 47,100 shares of Common Stock exercisable within 60 days of July 15, 2022.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20px; text-align: right"><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="width: 7px">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Represents options to purchase 24,883 shares of Common Stock, all of which are exercisable within 60 days of July 15, 2022.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20px; text-align: right"><FONT STYLE="font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="width: 7px">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes options to purchase 85,593 shares of Common Stock exercisable within 60 days of July 15, 2022.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20px; text-align: right"><FONT STYLE="font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="width: 7px">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes options to purchase 44,700 shares of Common Stock exercisable within 60 days of July 15, 2022.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20px; text-align: right"><FONT STYLE="font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="width: 7px">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes options to purchase 84,313 shares of Common Stock, which are exercisable within 60 days of July 15, 2022.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right; width: 20px"><FONT STYLE="font-size: 10pt">(8)</FONT></TD>
    <TD STYLE="text-align: justify; width: 7px">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes options to purchase 78,713 shares of Common Stock, all of which are exercisable within 60 days of July 15, 2022.&nbsp;&nbsp;Common Stock held by Steve Gorlin includes shares of Common Stock held by Mr. Gorlin&#8217;s wife.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20px; text-align: right"><FONT STYLE="font-size: 10pt">(9)</FONT></TD>
    <TD STYLE="width: 7px">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes options to purchase 78,513 shares of Common Stock, all of which are exercisable within 60 days July 15, 2022.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right; width: 20px"><FONT STYLE="font-size: 10pt">(10)</FONT></TD>
    <TD STYLE="text-align: justify; width: 7px">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes warrants to purchase 18,788 shares of Common Stock and options to purchase 83,875 shares of Common Stock, all of which are exercisable within 60 days of July 15, 2022.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20px; text-align: right"><FONT STYLE="font-size: 10pt">(11)</FONT></TD>
    <TD STYLE="width: 7px">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes options to purchase 79,500 shares of Common Stock, all of which are exercisable within 60 days of July 15, 2022.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20px; text-align: right"><FONT STYLE="font-size: 10pt">(12)</FONT></TD>
    <TD STYLE="width: 7px">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes warrants to purchase 13,606 shares of Common Stock and options to purchase 121,572 shares of Common Stock, all of which are exercisable within 60 days of July 15, 2022. Common Stock held by Michael Sherman includes 13,333 shares of the Common Stock held of record by Sherman Children&#8217;s Trust Brian Krisber, Trustee. All shares of Common Stock, warrants and options are deemed to be beneficially owned or controlled by Michael Sherman.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0">&nbsp;</P>
<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B><A NAME="a_004"></A>APPROVAL OF THE PIPE FINANCING FOR PURPOSES
OF NASDAQ RULE 5635</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0 0"><B>Purpose of the PIPE Financing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0 0; text-align: justify">Our Board of Directors believes it is in the
best interests of the Company to raise capital in the amount of $6.0 million in a private placement transaction to fund the working capital
needs of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0 0"><B>Description of the PIPE Financing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 15, 2022, the Company entered into a securities purchase agreement
(the &ldquo;Purchase Agreement&rdquo;) with the Purchaser, pursuant to which the Company agreed to issue and sell to the Purchaser, and
the Purchaser agreed to purchase from the Company, in a private placement, (i) an aggregate of 3,636,364 shares (the &ldquo;PIPE Shares&rdquo;)
of the Company&rsquo;s Class A common stock, par value $0.0001 per share (the &ldquo;Common Stock&rdquo;), at a price of $1.65 per share
and (ii) a warrant (the &ldquo;Warrant&rdquo;) to purchase up to a number of shares of Common Stock equal to 200% of the PIPE Shares (the
&ldquo;Warrant Shares&rdquo;) at an exercise price of $1.82, with a term of exercise of five years. The aggregate purchase price for the
PIPE Shares and the Warrant (collectively, the &ldquo;Securities&rdquo;) sold in the Private Placement was approximately $6.0 million.
The closing of the transactions contemplated by the Purchase Agreement is subject to customary closing conditions and is expected to occur
on or about ________ __, 2022, or approximately 20 days after the mailing of this Information Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0 0; text-align: justify">As required under Nasdaq Listing Rule 5630, the
independent directors with no interest in the PIPE Financing different from, or in addition to, the interests of the Company&#8217;s stockholders
generally negotiated the terms and conditions of the PIPE Financing and approved the PIPE Financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0 0; text-align: justify">The foregoing description of the Purchase Agreement is qualified in its entirety by reference
to the full and complete terms of the Purchase Agreement, which is filed as Exhibit 10.1 to the Company&rsquo;s Current Report on Form
8-K filed with the Securities and Exchange Commission on July 15, 2022, which is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0 0"><B>Reason for Stockholder Approval </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0 0; text-align: justify">Pursuant to Nasdaq Stock Market Listing
Rule 5635(c), if a company intends to issue securities to an officer, director, employee or consultant of the company at a price less
than the Current Market Price, the issuer generally must obtain the prior approval of its stockholders. Terren Peizer, the Company&rsquo;s
Chairman, is the direct beneficial owner of the Majority Stockholder, and as such, the PIPE Financing may be considered an issuance of
securities to a director of the Company. Moreover, the Current Market Price was $1.81 on July 14, 2022, therefore the purchase price
for the Securities is less than the Current Market Price. As a result, Nasdaq Rule 5635(c) requires that the Company obtain stockholder
approval prior to issuing the Securities to the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify">Pursuant to Nasdaq Stock Market Listing Rule
5635(d), if an issuer intends to issue securities in a transaction which could result in the issuance of 20% or more of the issued and
outstanding shares of the issuer&rsquo;s common stock on a pre-transaction basis for less than the Minimum Price for such stock, the issuer
generally must obtain the prior approval of its stockholders. The Minimum Price was $1.81 on July 14, 2022, therefore the purchase price
for the Securities is less than Minimum Price. In addition, as of July 14, 2022, the Company had 24,893,083 shares of Common Stock issued
and outstanding (the &ldquo;Outstanding Shares&rdquo;). The maximum number of shares of Common Stock to be issued to the Purchaser in
the PIPE Financing, assuming exercise in full of the Warrants, would result in the issuance of 10,909,092 shares, which is equal to 43.8%
of the Outstanding Shares on a pre-transaction basis. As a result, Nasdaq Rule 5635(d) requires that the Company obtain stockholder approval
prior to issuing the Securities in the PIPE Financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0 0; text-align: justify">To ensure compliance with Nasdaq Rule 5635, the
Purchase Agreement provides that the Company may not issue and the Purchaser may not purchase any Securities unless stockholder approval
is obtained for such issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0 0; text-align: justify"><B>Effect of the PIPE Financing on Existing Stockholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0 0; text-align: justify">The issuance of Securities pursuant to the Purchase
Agreement will not affect the rights of the holders of outstanding Common Stock, but such issuances will have a dilutive effect on the
Company&#8216;s existing stockholders, including the voting power and economic rights of the existing stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Subject to the satisfaction or waiver of the
conditions to the closing of the PIPE Financing, upon the closing of the
PIPE Financing, (i) 3,636,364 shares of Common Stock and (ii) warrants to purchase up to 7,272,728 shares of Common Stock will be issued
to the Majority Stockholder pursuant to the terms of the Purchase Agreement. Collectively, these issuances, assuming full exercise of
the Warrants, will represent approximately 43.8% of the issued and outstanding shares of Common Stock and will increase the beneficial
ownership of Mr. Peizer from approximately 78.2% to 84.8% of our issued and outstanding shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0 0"><B>Approval of the PIPE Financing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0 0; text-align: justify">The approval of the PIPE Financing, including
for purposes of Nasdaq Rule 5635, requires the approval of the holders of our outstanding Common Stock having not less than the minimum
number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were
present and voted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0 0; text-align: justify">The Majority Stockholder, the holder of 19,529,846 shares of Common Stock, or approximately 78.2% of the Outstanding
Shares entitled to vote on this corporate action, approved&nbsp;the PIPE Financing by a written consent in lieu of special meeting, the
form of which is attached hereto as <U>Exhibit A</U>. Accordingly, the limitations on issuances and sales of securities under Nasdaq Rule
5635 will not apply to the PIPE Financing. Pursuant to Rule 14c-2(b) promulgated under the Exchange Act, such action may not be effected
until at least 20 calendar days following the mailing of this Information Statement to our stockholders. This Information Statement is
first being mailed on or about ________ __, 2022 to the Company&rsquo;s stockholders of record as of the Record Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B><A NAME="a_005"></A>DISSENTERS&#8217; RIGHTS OF APPRAISAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0 0; text-align: justify">Under the General Corporation Law of the State
of Nevada, our stockholders are not entitled to appraisal rights with respect to the PIPE Financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0 0; text-align: center"><B><A NAME="a_006"></A>DELIVERY OF DOCUMENTS TO SECURITY HOLDERS SHARING
AN ADDRESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0 0; text-align: justify">Unless the Company is otherwise advised by the
stockholders, we will only deliver one copy of this Information Statement to multiple stockholders sharing an address. This practice known
as &#8220;householding&#8221; is intended to reduce the Company&#8217;s printing and postage costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0 0; text-align: justify">We will, upon request, promptly deliver a separate
copy of this Information Statement to a stockholder who shares an address with another stockholder. A stockholder, who wishes to receive
a separate copy of this Information Statement, may direct such request to the Company at 680 W Nye Lane Suite 201, Carson City, NV 89703,
or you can contact us via telephone at (775) 888-3162. Stockholders who receive multiple copies of the Information Statement at their
address and would like to request that only a single copy of communications be delivered to the shared address may do so by making either
a written or oral request to the Company contacts listed above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0; text-align: center"><B><A NAME="a_007"></A>WHERE
YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company files annual, quarterly and current
reports and other documents with the SEC. These reports contain additional information about BioVie. The Company&#8217;s SEC filings are
made available electronically to the public at the SEC&#8217;s website located at www.sec.gov. Stockholders can also obtain free copies
of the Company&#8217;s SEC filings through the &#8220;Investors&#8221; section of the Company&#8217;s website at www.biovieinc.com. The
Company&#8217;s website address is being provided as an inactive textual reference only. The information provided on the Company&#8217;s
website, other than the copies of the documents listed or referenced below that have been or will be filed with the SEC, is not part of
this Information Statement, and therefore is not incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The SEC allows the Company to &#8220;incorporate
by reference&#8221; information that it files with the SEC in other documents into this Information Statement. This means that the Company
may disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated
by reference is considered to be part of this Information Statement. This Information Statement and the information that the Company files
later with the SEC may update and supersede the information incorporated by reference. Such updated and superseded information will not,
except as so modified or superseded, constitute part of this Information Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company is incorporating by reference the
filings listed below and any additional documents that the Company may file with the SEC pursuant to Section 13(a), 13(c), 14 or 15(d)
of the Exchange Act on or after the date of the initial filing of this Information Statement and before the actions described in this
Information Statement become effective, except the Company is not incorporating by reference any information furnished (but not filed)
under Item 2.02 or Item 7.01 of any Current Report on Form 8-K and corresponding information furnished under Item 9.01 as an exhibit thereto:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 36px">&nbsp;</TD>
    <TD STYLE="width: 36px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Company&#8217;s Annual Report on Form 10-K for the fiscal year ended June 30, 2021 filed with the SEC on August 30, 2021 (the &#8220;2021 10-K&#8221;);</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 36px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Company&#8217;s definitive proxy statement on Schedule 14A filed with the SEC on September 14, 2021;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Company&#8217;s Quarterly Reports on Form 10-Q for the quarterly periods ended September 30, 2021, December 31, 2021 and March 31, 2022 filed with the SEC on November 10, 2021, February 8, 2022 and May 11, 2022, respectively; </FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36px">&nbsp;</TD>
    <TD STYLE="width: 36px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Company&#8217;s Current Reports on Form 8-K filed with the SEC on August 11, 2021, October
14, 2021, &nbsp;December 1, 2021, June 29, 2022, and July 15, 2022; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The description of the Company&#8217;s securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended, filed as Ex. 4.4 of the 2021 10-K.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company undertakes to provide without charge
to each person to whom a copy of this Information Statement has been delivered, upon request, by first class mail or other equally prompt
means, a copy of any or all of the documents incorporated by reference in this Information Statement, other than the exhibits to these
documents, unless the exhibits are specifically incorporated by reference into the information that this Information Statement incorporates.
You may obtain documents incorporated by reference by requesting them in writing at BioVie Inc., 680 W Nye Lane Suite 201, Carson City,
NV 89703 or by telephone at (775) 888-3162.</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_008"></A>OTHER
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company has not authorized anyone to provide
information on behalf of the Company that is different from that contained in this Information Statement. This Information Statement is
dated July 15, 2022. No assumption should be made that the information contained in this Information Statement is accurate as of any
date other than that date, and the mailing of this Information Statement will not create any implication to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company will make arrangements with brokerage
firms and other custodians, nominees and fiduciaries who are record holders of the Company&#8217;s Common Stock for the forwarding of
this Information Statement to the beneficial owners of the Company&#8217;s Common Stock. The Company will reimburse these brokers, custodians,
nominees and fiduciaries for the reasonable out-of-pocket expenses they incur in connection with the forwarding of the Information Statement.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 50%; padding: 0.25pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">By Order of the Board of Directors,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Cuong V. Do</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Chief Executive Officer</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Dated: July __, 2022</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0 0; text-align: center"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt/13.65pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>WRITTEN CONSENT<BR>
IN LIEU OF A MEETING<BR>
OF<BR>
THE MAJORITY STOCKHOLDER OF<BR>
OF<BR>
BIOVIE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to Section 78.320 of the Nevada Revised Statutes (the &#8220;<B>NRS</B>&#8221;) and Article II, Section 7 of the Amended and Restated
By-laws (the &#8220;<B>Bylaws</B>&#8221;) of BioVie Inc., a Nevada corporation (the &#8220;<B>Company</B>&#8221;), the undersigned stockholder
(the &#8220;<B>Majority Stockholder</B>&#8221;), which holds at least a majority of the issued and outstanding shares of the Company&#8217;s
Class A common stock, par value $0.0001 per share (the &#8220;<B>Common Stock</B>&#8221;), does hereby waive any and all notices that
may be required to be given with respect to a meeting of the stockholders and, in lieu of holding a special meeting of the stockholders,
hereby consents to the adoption of and hereby adopts by written consent the following resolution. Pursuant to Article II, Section 7 of
the Bylaws, prompt notice of the below action shall be given to those stockholders who have not consented in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B>WHEREAS</B>,
the board of directors of the Company (the &#8220;<B>Board</B>&#8221;) previously adopted and has determined that it is advisable, fair
to and in the best interests of the Company and its stockholders for the Company to enter into the Securities Purchase Agreement (the
&#8220;<B>Purchase Agreement</B>&#8221;), dated July 15, 2022, by and between the Company and Acuitas Group Holdings, LLC, a California
limited liability company, as purchaser (the &#8220;<B>Purchaser</B>&#8221;), in substantially the form attached hereto as <U>Exhibit
A</U>. For purposes of these resolutions, any capitalized terms used and not otherwise defined shall have the meaning ascribed to such
terms in the Purchase Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B>WHEREAS</B>,
on the terms and subject to the conditions set forth in the Purchase Agreement,
the Company will issue and sell to Purchaser (i) 3,636,364 shares of Common Stock (the &ldquo;<B>PIPE Shares</B>&rdquo;) and (ii) a warrant
(the &ldquo;<B>Warrant</B>&rdquo;) to purchase 7,272,728 shares of Common Stock (the &ldquo;<B>Warrant Shares</B>&rdquo;), as more fully
set forth in the Purchase Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B>WHEREAS</B>,
pursuant to Nasdaq Listing Rule 5635, stockholder approval is required for the issuance of the PIPE Shares, the Warrant and the Warrant
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><B>NOW,
THEREFORE, BE IT RESOLVED</B>, that the issuance of the PIPE Shares, the Warrant and the Warrant Shares, subject in each case to the terms
and conditions set forth in the Purchase Agreement, be and hereby is approved.&#9;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 45.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><I>[Signature page follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 14; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/100% Times New Roman, Times, Serif; margin: 0.05pt 0 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
the undersigned has duly executed this written consent on the date set forth below.</P>

<P STYLE="font: 10pt/100% Times New Roman, Times, Serif; margin: 0.05pt 0 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/13.55pt Times New Roman, Times, Serif; margin: 0 0 0 226.85pt">&nbsp;</P>




<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 7.0in; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt"><B>ACUITAS GROUP HOLDINGS, LLC</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; padding: 0.25pt"><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                            <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                            <P STYLE="margin-top: 0; margin-bottom: 0">Date: _____________</P></TD>
    <TD STYLE="width: 60%; padding: 0.25pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By: ___________________________</p>
    <P STYLE="text-indent: 20pt; font: 10pt Times New Roman, Times, Serif; margin: 0">Name: Terren S. Peizer</P>
    <P STYLE="text-indent: 20pt; font: 10pt Times New Roman, Times, Serif; margin: 0">Title: Chairman</P></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
